Cyclosporin A for pulmonary applications: a novel formulation approach
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Abschlussarbeit Buch |
| Sprache: | English |
| Veröffentlicht: |
2004
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | V, 178 S. Ill., graph. Darst. 21 cm |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV019684510 | ||
| 003 | DE-604 | ||
| 005 | 20060109 | ||
| 007 | t | ||
| 008 | 050203s2004 gw ad|| m||| 00||| eng d | ||
| 015 | |a 04,H06,1794 |2 dnb | ||
| 016 | 7 | |a 970708696 |2 DE-101 | |
| 035 | |a (OCoLC)58427352 | ||
| 035 | |a (DE-599)BVBBV019684510 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 0 | |a eng | |
| 044 | |a gw |c XA-DE | ||
| 049 | |a DE-91 |a DE-355 | ||
| 084 | |a CHE 893d |2 stub | ||
| 084 | |a 610 |2 sdnb | ||
| 100 | 1 | |a Eskandar, Fadi M. |d 1979- |e Verfasser |0 (DE-588)128854065 |4 aut | |
| 245 | 1 | 0 | |a Cyclosporin A for pulmonary applications |b a novel formulation approach |c by Fadi M. Eskandar |
| 264 | 1 | |c 2004 | |
| 300 | |a V, 178 S. |b Ill., graph. Darst. |c 21 cm | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 502 | |a Kiel, Univ., Diss., 2004 | ||
| 650 | 0 | 7 | |a Ciclosporin |0 (DE-588)4121097-9 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Lungenkrankheit |0 (DE-588)4036660-1 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)4113937-9 |a Hochschulschrift |2 gnd-content | |
| 689 | 0 | 0 | |a Ciclosporin |0 (DE-588)4121097-9 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Ciclosporin |0 (DE-588)4121097-9 |D s |
| 689 | 1 | 1 | |a Lungenkrankheit |0 (DE-588)4036660-1 |D s |
| 689 | 1 | |C b |5 DE-604 | |
| 856 | 4 | 2 | |m GBV Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=013012427&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-013012427 | ||
Datensatz im Suchindex
| _version_ | 1804133126540099584 |
|---|---|
| adam_text | TABLE OF CONTENTS TABLE OF CONTENTS / INTRODUCTION AND OBJECTIVES.... /
/./ INTRODUCTION 1 1.2 OBJECTIVES 3 2 THEORETICAL BACKGROUND 4 2.1
CYCLOSPORIN A 4 2.1.1 THE HISTORY OF CYCLOSPORIN A 4 2.1.2 CHEMISTRY OF
CYCLOSPORIN 8 2.1.3 MECHANISM OF ACTION 9 2.1.4 CYCLOSPORIN A
FORMULATION AND HIOAVAILAHILITY 11 2.2 PULMONARY APPLICATION 13 2.2.1
LUNG ANATOMY AND PHYSIOLOGY 13 2.2.2 PULMONARY BARRIERS AND DEFENSE
MECHANISMS IS 2.2.3 PARTICLE DEPOSITION IN THE RESPIRATORY TRACT 16 2.3
PHARMACEUTICAL AEROSOLS 18 2.3.1 DEVELOPMENT OF INHALATION DRUG DELIVERY
IS 2.3.2 DESCRIPTION OF AEROSOL PARTICLE SIZE 20 2.3.3 PULMONARY
DELIVERY OF THERAPEUTIC PEPTIDES AND PROTEINS 22 2.4 NEBTTLIZATION DRUG
DELIVERY 25 2.4.1 HISTORICAL PERSPECTIVE 25 2.4.2 NEBULIZATION
TECHNIQUES 26 2.4.3 NEBULIZER PERFORMANCE 31 2.4.4 NEBULIZER SOLUTION
AND SUSPENSION FORMULATIONS 33 2.4.5 FACTORS AFFECTING NEBULIZER
PERFORMANCE 34 3 EXPERIMENTAL METHODS 37 3.1 CYCLOSPORIN A
CHARACTERIZATION 37 3.1.1 PHYSICOCHEMICAL CHARACTERIZATION 37 TABLE OF
CONTENTS 3.1.2 CSA ANALYSIS 39 3.2 CSA SUSPENSIONS 40 3.2.1 PREPARATION
OF CSA SUSPENSIONS 40 3.2.2 CHARACTERIZATION OF CSA SUSPENSIONS 41 3.3
AEROSOLIZATION 44 3.3.1 NEBULIZATION OF CSA SUSPENSIONS 44 3.3.2 AEROSOL
PERFORMANCE CHARACTERIZATION 45 3.4 STATISTICAL ANALYSIS 48 4
CHARACTERIZATION OF CYCLOSPORIN A 49 4.1 CSA QUALITATIVE AND
QUANTITATIVE ANALYSIS 49 4.1.1 CSA IDENTIFICATION TEST 49 4.1.2
QUALITATIVE ANALYSIS OF CSA DEGRADATION PRODUCTS 50 4.1.3 QUANTITATIVE
ANALYSIS OF CSA 51 4.2 CSA PHYSICOCHEMICAL CHARACTERS 52 4.2.1 CSA
HYDROPHOBIC CHARACTER 52 4.2.2 CSA SOLUBILITY 53 4.2.3 CSA CRYSTAL
PROPERTIES 54 4.2.4 CSA MOISTURE CONTENT AND WATER SORPTION CHARACTER 55
4.3 CSA STABILITY TESTS 56 4.3.1 EFFECT OF PH-VATUE 56 4.3.2 EFFECT OF
STORAGE TEMPERATURE 57 4.3.3 CSA LIGHT SENSITIVITY 58 5 PREFORMULA TION.
59 5.1 CSA PARTICLE SIZE REDUCTION 59 5.1.1 CSA MICRONIZATION 59 5.1.2
HIGH PRESSURE HOMOGENIZATION 61 5.2 CHOICE OFEXCIPIENTS 63 TABLE OF
CONTENTS 5.2./ BUFFERING SYSTEM 63 5.2.2 SURFACTANT 67 5.2.3
SURFACTANT/CO-SURFACTANT COMBINATION 72 5.2.4 LONG-TERM CSA
PREFORMULATION STABILITY 86 5.2.5 ADDITION OF AN EXCESS OF STABILIZER 81
6 CYCLOSPORIN A MICROSUSPENSIONS 86 6.1 FORMULATION 86 6.2
CHARACTERIZATION 86 6.3 STABILITY STUDIES 88 6.4 NEBULIZATION STUDIES 90
6.4.1 INHALATION TIME MEASUREMENTS 90 6.4.2 CSA OUTPUT RATE AND RESIDUAL
AMOUNT 92 6.4.3 CSA DELIVERY EFFICIENCY 93 7 METHOD OPTIMIZA TION 95 7.1
INSITU-MICRONIZATION 95 7.2 HIGH PRESSURE HOMOGENIZATION 96 7.2.1 EFFECT
OF HOMOGENIZATION PRESSURE 99 7.2.2 EFFECT OF TEMPERATURE 100 7.3
PACKAGING OF CSA NANO-SIISPENSIONS 101 8 CYCLOSPORIN A
NANOSUSPENSIONS... 103 8.1 CSA NANO- AND MICROSUSPENSIONS 103 8.1.1
PARTICLE SIZE MEASUREMENTS 103 8.1.2 NEBULIZATION STUDIES 104 8.2
LONG-TERM STABILITY STUDIES 108 9 EFFECT OF VISCOSITY ILL 9.1
FORMULATION 111 TABLE OF CONTENTS 9.2 CHARACTERIZATION 111 9.3 STABILITY
STUDIES 113 9.4 NEBULIZATION STUDIES 114 9.4.1 INHALATION TIME
MEASUREMENTS 114 9.4.2 CSA OUTPUT RATE AND RESIDUAL DRUG AMOUNT 115
9.4.3 CSA DELIVERY EFFICIENCY 117 10 EFFECT OF SURFACE TENSION. ,. 119
10.1 FORMULATION 119 10.2 CHARACTERIZATION 119 10.3 STABILITY STUDIES
121 10.4 NEBULIZATION STUDIES 123 10.4.1 INHALATION TIME MEASUREMENTS
123 10.4.2 CSA OUTPUT RATE AND RESIDUAL AMOUNT 124 10.4.3 CSA DELIVERY
EFFICIENCY 127 11 EFFECT OF CO-SURFACTANT. 129 11.1 FORMULATION 129 11.2
CHARACTERIZATION 129 11.3 STABILITY STUDIES 131 11.4 NEBULIZATION
STUDIES 132 11.4.1 INHALATION TIME MEASUREMENTS 133 11.4.2 CSA OUTPUT
RATE AND RESIDUAL AMOUNT 134 11.4.3 CSA DELIVERY EFFICIENCY 136 11.4.4
EFFECT OF NEBULIZATION ON SUSPENSION PARTICLE SIZE 13 7 11.5
STERILIZATION 137 12 CYCLODEXTRINS 140 12.1 FORMULATION 140 TABLE OF
CONTENTS 12.2 CHARACTERIZATION 140 12.3 SUSPENSION PARTICLE SIZE
ANALYSIS 142 12.4 NEBULIZATION STUDIES 143 12.4.1 INHALATION TIME
MEASUREMENTS 143 12.4.2 CSA OUTPUT RATE AND RESIDUAL AMOUNT 144 12.4.3
CSA DELIVERY EFFICIENCY 146 13 NEBULIZER PERFORMANCE. 148 13.1
NEBULIZERS USED 148 13.2 NEBULIZATION STUDIES 148 13.2.1 INHALATION TIME
MEASUREMENTS 148 13.2.2 CSA OUTPUT RATE AND RESIDUAL AMOUNT 150 13.2.3
CSA DELIVERY EFFICIENCY 152 14 SUMMARY 154 15 ZUSAMMENFASSUNG 156 16
APPENDIX ....159 16.1 MATERIALS 159 16.2 LIST OF ABBREVIATIONS 161 17
REFERENCES 163 ACKNOWLEDGEMENTS 180 CURRICULUM VITAE 182
|
| any_adam_object | 1 |
| author | Eskandar, Fadi M. 1979- |
| author_GND | (DE-588)128854065 |
| author_facet | Eskandar, Fadi M. 1979- |
| author_role | aut |
| author_sort | Eskandar, Fadi M. 1979- |
| author_variant | f m e fm fme |
| building | Verbundindex |
| bvnumber | BV019684510 |
| classification_tum | CHE 893d |
| ctrlnum | (OCoLC)58427352 (DE-599)BVBBV019684510 |
| discipline | Chemie Medizin |
| format | Thesis Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01557nam a2200421 c 4500</leader><controlfield tag="001">BV019684510</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20060109 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">050203s2004 gw ad|| m||| 00||| eng d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">04,H06,1794</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">970708696</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)58427352</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV019684510</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-91</subfield><subfield code="a">DE-355</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">CHE 893d</subfield><subfield code="2">stub</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Eskandar, Fadi M.</subfield><subfield code="d">1979-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)128854065</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cyclosporin A for pulmonary applications</subfield><subfield code="b">a novel formulation approach</subfield><subfield code="c">by Fadi M. Eskandar</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">V, 178 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield><subfield code="c">21 cm</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="502" ind1=" " ind2=" "><subfield code="a">Kiel, Univ., Diss., 2004</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Ciclosporin</subfield><subfield code="0">(DE-588)4121097-9</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Lungenkrankheit</subfield><subfield code="0">(DE-588)4036660-1</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)4113937-9</subfield><subfield code="a">Hochschulschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Ciclosporin</subfield><subfield code="0">(DE-588)4121097-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Ciclosporin</subfield><subfield code="0">(DE-588)4121097-9</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Lungenkrankheit</subfield><subfield code="0">(DE-588)4036660-1</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="C">b</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">GBV Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=013012427&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-013012427</subfield></datafield></record></collection> |
| genre | (DE-588)4113937-9 Hochschulschrift gnd-content |
| genre_facet | Hochschulschrift |
| id | DE-604.BV019684510 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T20:03:46Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-013012427 |
| oclc_num | 58427352 |
| open_access_boolean | |
| owner | DE-91 DE-BY-TUM DE-355 DE-BY-UBR |
| owner_facet | DE-91 DE-BY-TUM DE-355 DE-BY-UBR |
| physical | V, 178 S. Ill., graph. Darst. 21 cm |
| publishDate | 2004 |
| publishDateSearch | 2004 |
| publishDateSort | 2004 |
| record_format | marc |
| spelling | Eskandar, Fadi M. 1979- Verfasser (DE-588)128854065 aut Cyclosporin A for pulmonary applications a novel formulation approach by Fadi M. Eskandar 2004 V, 178 S. Ill., graph. Darst. 21 cm txt rdacontent n rdamedia nc rdacarrier Kiel, Univ., Diss., 2004 Ciclosporin (DE-588)4121097-9 gnd rswk-swf Lungenkrankheit (DE-588)4036660-1 gnd rswk-swf (DE-588)4113937-9 Hochschulschrift gnd-content Ciclosporin (DE-588)4121097-9 s DE-604 Lungenkrankheit (DE-588)4036660-1 s b DE-604 GBV Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=013012427&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Eskandar, Fadi M. 1979- Cyclosporin A for pulmonary applications a novel formulation approach Ciclosporin (DE-588)4121097-9 gnd Lungenkrankheit (DE-588)4036660-1 gnd |
| subject_GND | (DE-588)4121097-9 (DE-588)4036660-1 (DE-588)4113937-9 |
| title | Cyclosporin A for pulmonary applications a novel formulation approach |
| title_auth | Cyclosporin A for pulmonary applications a novel formulation approach |
| title_exact_search | Cyclosporin A for pulmonary applications a novel formulation approach |
| title_full | Cyclosporin A for pulmonary applications a novel formulation approach by Fadi M. Eskandar |
| title_fullStr | Cyclosporin A for pulmonary applications a novel formulation approach by Fadi M. Eskandar |
| title_full_unstemmed | Cyclosporin A for pulmonary applications a novel formulation approach by Fadi M. Eskandar |
| title_short | Cyclosporin A for pulmonary applications |
| title_sort | cyclosporin a for pulmonary applications a novel formulation approach |
| title_sub | a novel formulation approach |
| topic | Ciclosporin (DE-588)4121097-9 gnd Lungenkrankheit (DE-588)4036660-1 gnd |
| topic_facet | Ciclosporin Lungenkrankheit Hochschulschrift |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=013012427&sequence=000001&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT eskandarfadim cyclosporinaforpulmonaryapplicationsanovelformulationapproach |